CCIA
NRIX icon

Campbell & Co Investment Adviser’s Nurix Therapeutics NRIX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-22,056
Closed -$496K – 1266
2024
Q3 		$496K Buy
22,056
+2,319
+12% +$52.5K 0.04% 723
2024
Q2 		$412K Sell
19,737
-32,092
-62% -$500K 0.04% 722
2024
Q1 		$762K Buy
+51,829
New +$557K 0.07% 509

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Campbell & Co Investment Adviser's NRIX Position: Q4 2024 in Review

Campbell & Co Investment Adviser sold out of Nurix Therapeutics (NRIX) in Q4 2024, closing a stake of 22,056 shares — an estimated $496K sold.

Campbell & Co Investment Adviser first reported a position in NRIX in Q1 2024 and held it in 3 quarters. The position peaked at $762K in Q1 2024. 175 funds tracked by Wall St. Rank hold NRIX as of Q4 2024.

  • Campbell & Co Investment Adviser reported no remaining Nurix Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 22,056 Nurix Therapeutics shares in Q4 2024, an estimated $496K.
  • Campbell & Co Investment Adviser first reported a position in Nurix Therapeutics in Q1 2024 and held it in 3 quarters.
  • Campbell & Co Investment Adviser's Nurix Therapeutics position peaked at $762K in Q1 2024.
  • 175 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2024.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2024, filed 10 Feb 2025.